It’s the end of the month--and the half year mark--so we open up today's monthly discussion with Nathan and Laura to include some of the headlines we’ve missed this year.
Last month a paper was published warning about the off target effects when using CRISPR. Laura and Nathan agree the kerfuffle which exploded into this month was more about Wall Street than adding anything new to science.
Remember the technology we used before CRISPR? Sangamo Biosciences launched the first ever “in vivo” (in human) trial for gene editing using Zinc Finger technology.